Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News MaxCyte Inc MXCT

Technology Scientific & Technical Instruments
MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by... see more

Recent & Breaking News (NDAQ:MXCT)

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

GlobeNewswire November 13, 2024

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

GlobeNewswire November 6, 2024

MaxCyte to Participate in Two Upcoming Investor Conferences

GlobeNewswire October 31, 2024

MaxCyte Appoints Cynthia Collins to its Board of Directors

GlobeNewswire October 15, 2024

MaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024

GlobeNewswire October 11, 2024

MaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer

GlobeNewswire October 10, 2024

MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases

GlobeNewswire September 16, 2024

MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference

GlobeNewswire September 5, 2024

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

GlobeNewswire August 6, 2024

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

GlobeNewswire July 9, 2024

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

GlobeNewswire May 29, 2024

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

GlobeNewswire May 22, 2024

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

GlobeNewswire May 7, 2024

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

GlobeNewswire April 10, 2024

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

GlobeNewswire April 2, 2024

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

GlobeNewswire March 12, 2024

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

GlobeNewswire March 4, 2024

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

GlobeNewswire February 9, 2024

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

GlobeNewswire January 30, 2024

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

GlobeNewswire January 23, 2024